Johns Hopkins researchers stumbled upon mutations associated with familial partial lipodystrophy (FPLD), a rare disease that disrupts normal patterns of fat distribution throughout the body while studying a protein that gives structure to the nucleus of cells.
"Our findings open new paths for learning how and why fat cells are disproportionately affected by mutations in the protein lamin A, which is found in the nucleus of most cells of the body," says Katherine Wilson, Ph.D., professor of cell biology at the Johns Hopkins University School of Medicine.
According to the researchers, this is the first report that another protein, SUMO1, can attach to lamin A. Importantly, they found that FPLD-causing mutations in lamin A prevent this attachment. Details of the study were published in the Feb. 1 issue of the journal Molecular Biology of the Cell.
When the Wilson group made their discovery, they were studying lamin A binding to another protein, actin. Actin can sometimes form a complex with certain SUMO proteins, small proteins often attached to other proteins to alter their functions, their locations and their interactions with additional proteins.
"Sometimes you go into an experiment looking for one thing but you find another," says Wilson. "We wanted to know if lamin A could bind to actin-SUMO1 complexes. Instead, we found that SUMO1 itself attaches to lamin A."
SUMO1 is usually attached to proteins at sites with certain properties; these sites can be predicted by the surrounding amino acids, the basic building blocks of proteins whose blueprints are found in genes. So the researchers searched lamin A's amino acid sequence for predicted binding sites and found five. Using targeted genetic techniques, they created lamin A variants, each with a mutation at a different predicted SUMO1 attachment site. They then added SUMO1 to the mutants and tested whether it could attach to them or not.
Two mutations significantly decreased SUMO1 attachment. One was at a predicted site; the other was unexpectedly in their comparison "control" variant. "Since the mutation site in our control variant was not a predicted SUMO1 attachment site, we were curious about it," explains Wilson. "Mutations in lamin A cause more than 15 different diseases, so we checked the genetic database to see if any diseases were associated with mutations near the SUMO1 attachment site, and FPLD leapt out like a neon sign."
FPLD is a very rare condition that starts around puberty. Fat on the legs of patients is reduced while it accumulates at other locations, including the neck and face. Patients can also become diabetic.
Twenty-four different mutations in lamin A can cause FPLD. To see if two other FPLD-causing mutations near the SUMO1 attachment site affected SUMO1 attachment, the team created these variants and tested them as before. One of the new variants did show decreased SUMO1 attachment. Based on the location of that mutation and one of the other SUMO1-disrupting mutations, the researchers were able to identify a "patch" on the surface of the lamin A protein that is important for SUMO1 attachment.
Exactly how lamin A and SUMO1 connect to FPLD is still a mystery. "We can only speculate on how lamin A and SUMO1 work together to regulate fat cells," says Wilson. "But these results raise new research questions that will hopefully move FPLD studies forward."